Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials
Yongping Liu, Jun Meng, Guichan Wang Department of Gynecology, Obstetrics, Yuhuangding Hospital, Yantai, Shandong Province, People’s Republic of China Aims: We aimed to comprehensively assess the risk of gastrointestinal toxicities associated with poly (ADP-ribose) polymerase inhibitors (P...
Saved in:
Main Authors: | Liu Y (Author), Meng J (Author), Wang G (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2018-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer
by: Chia-Hao Liu, et al.
Published: (2017) -
Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
by: Stephen A. Jannetti, et al.
Published: (2020) -
Targeted therapy with Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of solid tumours
by: Faustyna Piędel, et al.
Published: (2020) -
Potential biological role of poly (ADP-ribose) polymerase (PARP) in male gametes
by: Sarkar Oli, et al.
Published: (2009) -
Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer
by: Ruihong Dong, et al.
Published: (2023)